Foghorn Therapeutics Inc. (FHTX)

NASDAQ: FHTX · IEX Real-Time Price · USD
8.51
+0.13 (1.55%)
Jan 27, 2023, 4:00 PM EST - Market closed

Company Description

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system.

The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.

The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers.

It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines.

Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.
Foghorn Therapeutics logo
Country United States
Founded 2015
IPO Date Oct 23, 2020
Industry Biotechnology
Sector Healthcare
Employees 119
CEO Mr. Adrian H. B. Gottschalk

Contact Details

Address:
500 Technology Square, Suite 700
Cambridge, Massachusetts 02139
United States
Phone 617-586-3100
Website foghorntx.com

Stock Details

Ticker Symbol FHTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001822462
CUSIP Number 344174107
ISIN Number US3441741077
SIC Code 2834

Key Executives

Name Position
Adrian H. B. Gottschalk President, Chief Executive Officer and Director
Dr. Allan Reine M.D. Chief Financial Officer
Dr. Samuel Agresta M.D., M.P.H. Chief Medical Officer
Dr. Gerald R. Crabtree M.d. Founder and Member of Scientific Advisory Board
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer
Ben Strain Vice President of Investor Relations and Corporate Communications
Michael J. LaCascia Chief Legal Officer
Saurabh Sewak Ph.D. Vice President of Corporate Development
Carlos Costa Chief People Officer
Fanny Cavalie Chief Strategy and Business Operations Officer

Latest SEC Filings

Date Type Title
Jan 9, 2023 8-K Current Report
Nov 8, 2022 10-Q Quarterly Report
Nov 8, 2022 8-K Current Report
Oct 27, 2022 8-K Current Report
Oct 26, 2022 8-K Current Report
Aug 31, 2022 8-K Current Report
Aug 23, 2022 8-K Current Report
Aug 17, 2022 8-K Current Report
Aug 9, 2022 10-Q Quarterly Report
Aug 9, 2022 10-K/A [Amend] Annual report